Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;25(8):2306-2320.
doi: 10.1007/s12094-023-03126-4. Epub 2023 Apr 19.

Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity

Affiliations
Review

Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity

Minjie Pan et al. Clin Transl Oncol. 2023 Aug.

Abstract

Chemokines are chemotactic-competent molecules composed of a family of small cytokines, playing a key role in regulating tumor progression. The roles of chemokines in antitumor immune responses are of great interest. CXCL9, CXCL10, and CXCL11 are important members of chemokines. It has been widely investigated that these three chemokines can bind to their common receptor CXCR3 and regulate the differentiation, migration, and tumor infiltration of immune cells, directly or indirectly affecting tumor growth and metastasis. Here, we summarize the mechanism of how the CXCL9/10/11-CXCR3 axis affects the tumor microenvironment, and list the latest researches to find out how this axis predicts the prognosis of different cancers. In addition, immunotherapy improves the survival of tumor patients, but some patients show drug resistance. Studies have found that the regulation of CXCL9/10/11-CXCR3 on the tumor microenvironment is involved in the process of changing immunotherapy resistance. Here we also describe new approaches to restoring sensitivity to immune checkpoint inhibitors through the CXCL9/10/11-CXCR3 axis.

Keywords: CXCL9/10/11; CXCR3; Immune cells; Immunotherapy resistance.

PubMed Disclaimer

References

    1. Front Immunol. 2019 Feb 05;10:128 - PubMed
    1. Cancer Res. 2007 Jun 15;67(12):5940-8 - PubMed
    1. Int J Mol Sci. 2020 Nov 14;21(22): - PubMed
    1. Cancer Cell. 2017 May 8;31(5):711-723.e4 - PubMed
    1. Mol Ther. 2016 Jun;24(6):1135-1149 - PubMed

LinkOut - more resources